ATE215124T1 - Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen - Google Patents
Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungenInfo
- Publication number
- ATE215124T1 ATE215124T1 AT94921762T AT94921762T ATE215124T1 AT E215124 T1 ATE215124 T1 AT E215124T1 AT 94921762 T AT94921762 T AT 94921762T AT 94921762 T AT94921762 T AT 94921762T AT E215124 T1 ATE215124 T1 AT E215124T1
- Authority
- AT
- Austria
- Prior art keywords
- tetc
- vaccine compositions
- fusion protein
- fusion proteins
- compositions containing
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 4
- 241000894006 Bacteria Species 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108010055044 Tetanus Toxin Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 abstract 1
- 108010077515 glycylproline Proteins 0.000 abstract 1
- 229940118376 tetanus toxin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C12N9/1088—Glutathione transferase (2.5.1.18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB1993/001617 WO1994003615A1 (en) | 1992-07-31 | 1993-07-30 | Expression of recombinant fusion proteins in attenuated bacteria |
| GB9401787A GB9401787D0 (en) | 1994-01-31 | 1994-01-31 | Vaccine compositions |
| PCT/GB1994/001647 WO1995004151A2 (en) | 1993-07-30 | 1994-07-29 | Vaccine compositions containing recombinant tetc-fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE215124T1 true ATE215124T1 (de) | 2002-04-15 |
Family
ID=26302349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94921762T ATE215124T1 (de) | 1993-07-30 | 1994-07-29 | Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0712442B1 (de) |
| JP (1) | JPH09500540A (de) |
| AT (1) | ATE215124T1 (de) |
| AU (1) | AU7235794A (de) |
| CA (1) | CA2168459C (de) |
| DE (1) | DE69430246T2 (de) |
| WO (1) | WO1995004151A2 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0996717B1 (de) * | 1997-08-05 | 2005-12-07 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Immunschützendes influenzaantigen und dessen verwendung zur impfung |
| US7923015B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
| US7923216B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
| ATE352558T1 (de) * | 1997-08-14 | 2007-02-15 | Pasteur Institut | Hybdride tetanustoxinproteine die rückwirkend und transsynatisch ins zns migrieren |
| GB9720033D0 (en) * | 1997-09-19 | 1997-11-19 | Medeva Plc | Hepatitis B virus polypeptides |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
| US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| GB9916363D0 (en) * | 1999-07-13 | 1999-09-15 | Univ Bristol | Methods of suppressing cell growth |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| EP1356820A1 (de) * | 2002-04-26 | 2003-10-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | DNA-Impfstoff kombiniert mit einen Apoptoneauslöser von Tumorzellen |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| ES2317043T3 (es) | 2003-06-23 | 2009-04-16 | Baxter International Inc. | Proteinas portadoras para vacunas. |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| EP1838348B1 (de) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanisierte amyloid-beta-antikörper zur verbesserung der kognition |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2921574B2 (ja) * | 1988-02-01 | 1999-07-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンの担体分子としてのｔ細胞のエピトープ |
| CA2031468A1 (en) * | 1989-12-08 | 1991-06-09 | Mitchell S. Gross | Malaria vaccine |
| FR2656626B1 (fr) * | 1989-12-29 | 1994-08-12 | Pasteur Institut | Fragment peptidique comprenant une sequence issue de la proteine 28 kda de schistosoma mansoni et compositions vaccinantes et/ou therapeutiques comprenant ledit fragment. |
| SK55593A3 (en) * | 1991-03-05 | 1993-10-06 | Wellcome Found | Expresion of recombinant proteins in attenuated bacteria |
| AU2699192A (en) * | 1991-10-16 | 1993-05-21 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
| CA2141427C (en) * | 1992-07-31 | 2008-07-22 | Mohammed Anjam Khan | Expression of recombinant fusion proteins in attenuated bacteria |
-
1994
- 1994-07-29 JP JP7505668A patent/JPH09500540A/ja active Pending
- 1994-07-29 CA CA002168459A patent/CA2168459C/en not_active Expired - Fee Related
- 1994-07-29 DE DE69430246T patent/DE69430246T2/de not_active Expired - Fee Related
- 1994-07-29 AT AT94921762T patent/ATE215124T1/de not_active IP Right Cessation
- 1994-07-29 AU AU72357/94A patent/AU7235794A/en not_active Abandoned
- 1994-07-29 WO PCT/GB1994/001647 patent/WO1995004151A2/en not_active Ceased
- 1994-07-29 EP EP94921762A patent/EP0712442B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2168459C (en) | 2002-10-01 |
| EP0712442B1 (de) | 2002-03-27 |
| CA2168459A1 (en) | 1995-02-09 |
| AU7235794A (en) | 1995-02-28 |
| WO1995004151A2 (en) | 1995-02-09 |
| EP0712442A1 (de) | 1996-05-22 |
| JPH09500540A (ja) | 1997-01-21 |
| DE69430246T2 (de) | 2002-12-12 |
| DE69430246D1 (de) | 2002-05-02 |
| WO1995004151A3 (en) | 1995-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69430246D1 (de) | Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen | |
| DK0574466T3 (da) | Udtrykkelse af rekombinante proteiner i svækkede bakterier | |
| WO2005071088A3 (en) | Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof | |
| EP0722461A4 (de) | Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird | |
| YU193887A (en) | PROCESS FOR OBTAINING APOLYPOPROTEINE "Al" | |
| DE69034100D1 (de) | Verktorvermittelte genominsertion und expression von dna in bcg | |
| GB2295394A (en) | Vaccine Compositions | |
| HU9501832D0 (en) | Improved vaccine for immunisation aga inst tbe virus infections as well as method for preparing them | |
| KR970700770A (ko) | Htra-프로모터를 사용하여 독성이 약화된 박테리아내에서 이종 단백질을 발현시키는 방법(expression of heterologous proteins in attenuated bacteria using the htra-promoters) | |
| ATE174963T1 (de) | Klonierung und expression eines rhoptry- assoziierten proteins aus p. falciparum | |
| DK1241186T4 (da) | Humant vækststandsende specifikt gen-6 (gas-6) og nukleinsyrer kodende derfor | |
| DK1328621T3 (da) | 13245, en ny human proteinkinase af den myotoniske dystrofitype og anvendelser deraf | |
| DE69943058D1 (de) | Loslösendes protein 5 - ucp5 | |
| DK1241251T3 (da) | Humant prostasin-lignende protein og nukleinsyrer kodende for samme | |
| DK1241184T3 (da) | Humant synaptogyrin-lignende protein og nukleinsyrer kodende for dette | |
| HK1098673A1 (zh) | 重组编码融合蛋白的核酸分子，该融合蛋白包括抗原和细菌分泌的信号多肽，表达框架，和细菌，及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |